Shopping Cart

Your shopping cart is currently empty

Gliclazide

Name: Gliclazide
Brand: TargetMol
SKU: T1527
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1527Cas No. 21187-98-4

Alias SE1702, S1702

Gliclazide (SE1702), an oral antihyperglycemic agent, belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating beta-cells of the pancreas to release insulin.

Gliclazide

Copy Product Info

🥰Excellent

Purity: 99.63%

Catalog No. T1527Alias SE1702, S1702Cas No. 21187-98-4

Gliclazide (SE1702), an oral antihyperglycemic agent, belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating beta-cells of the pancreas to release insulin.

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
500 mg	$29	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$37	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.63%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Gliclazide AI Summary

Gliclazide exhibits multifaceted biological activities, prominently demonstrating significant antihyperglycemic and antidiabetic properties. In sucrose-loaded and streptozotocin-induced diabetic Sprague-Dawley rats, it reduces blood glucose levels by 40.4% and 27.7%, respectively, at an oral dosage of 100 mg/kg. It also shows similar activity in various other hyperglycemic and diabetic animal models, including a 44.8% glucose reduction in sucrose-challenged Charles Foster/Wistar rats and a 17.4% reduction in C57BL/Ks db/db mice. Additionally, it modulates human MRP2-mediated estradiol-17-beta-glucuronide transport with an activity level of 174.0%. The compound impacts various enzymes and cellular functions, inhibiting ALDH1A1 (39810.7 nM), lipid storage modulation in Drosophila cells (4.6 nM), Bacillus subtilis PPTase (31622.8 nM), Fructose-1,6-bisphosphate Aldolase (8912.5 nM), and others. It also attenuates virus entry, showing moderate antiviral activity against SARS-CoV-2 and Marburg Virus with potencies greater than 20000.0 nM and 3548.1 nM, respectively. Pharmacokinetically, Gliclazide has a pKa of 5.98, low plasma protein binding (logFu = 0.09), and a moderate volume of distribution (Vdss = 0.36 L.kg-1). However, it poses a moderate hepatotoxicity risk with elevated hepatic function markers and a combined HepSE score of 4.0, indicating potential liver injury. It affects various physiological parameters such as liver and kidney function, electrolyte balance, and lipid metabolism. Additionally, Gliclazide stimulates glucose-stimulated insulin secretion in rat INS1 cells, highlighting a notable effect on insulin secretion and potentially beneficial metabolic impacts. Despite these positive activities, its bioactivity against certain human BSEP, MRP transporters, and select enzymes like AKR1C1 and AKR1C2 remains negligible, with IC50 values generally exceeding 1000000.0 nM..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Gliclazide (SE1702), an oral antihyperglycemic agent, belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating beta-cells of the pancreas to release insulin.
Targets&IC50	K+ channel:184 nM
Synonyms	SE1702, S1702

Chemical Properties

Molecular Weight	323.41
Formula	C₁₅H₂₁N₃O₃S
Cas No.	21187-98-4
Smiles	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1
Relative Density.	1.35 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 250 mg/mL (773.01 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.18 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.0921 mL	15.4603 mL	30.9205 mL	154.6025 mL
5 mM	0.6184 mL	3.0921 mL	6.1841 mL	30.9205 mL
10 mM	0.3092 mL	1.5460 mL	3.0921 mL	15.4603 mL
20 mM	0.1546 mL	0.7730 mL	1.5460 mL	7.7301 mL
50 mM	0.0618 mL	0.3092 mL	0.6184 mL	3.0921 mL
100 mM	0.0309 mL	0.1546 mL	0.3092 mL	1.5460 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc